Orlistat (C09-0994-530)

Lipase Inhibitor, THL (Tetrahydrolipstatin), is a compound that has been shown to rapidly inactivate lipoprotein lipase (LPL). This agent has been found to bind both subunits of LPL, induce tetramerisation, and cause local conformational changes. The exception to lipase inhibition capacities of THL is phospholipase A2, which is not affected by THL. Mechanistic studies suggest that THL inhibits the thioesterase domain of fatty acid synthase (FAS) and as a result halts cell proliferation and causes cell apoptosis. More detailed experiments show that gradually THL affects the retinoblastoma protein pathway and leads to cell-cycle arrest at G1/S boundary. Lipase Inhibitor, THL is an inhibitor of pancreatic and gastric lipase, as well as carboxyl ester lipase (CEL) and diacylglycerol lipase-α (DAGLα). Lipase Inhibitor, THL also activates caspase-3.Orlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. Specification: >97.0%(HPLC) MDL Number: MFCD05662360 Molecular Formula: C29H53NO5 Molecular Weight: 495.75 PubChem CID: 3034010 Isomeric SMILES: CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/O159936-SCI_ea80eae331ce6514727734c11557e09f.pdf